Quarterly lobbying tallies are out, and I’m not impressed (but I’m a little confused)
Drug makers spent about what they typically spend on lobbying in the third quarter of 2019, according to the latest disclosures. Reports for many of the industries’ biggest players, including PhRMA, weren’t available when we last checked, but it’s still striking that there weren't more splashy figures, given the ever-growing bipartisan furor over high drug prices.
Drug makers have typically spared no expense lobbying the federal government and in recent years have steadily increased the money they spend on lobbying, but that doesn’t seem to be the case this quarter. Take Johnson & Johnson, for example, which spent $810,000 on lobbying this quarter. That’s way down from the $2.15 million they spent last quarter and the $1.9 million the company spent this time last year. The difference in spending isn’t quite so stark for most companies and groups, to be fair — BIO, for example, spent $3.08 million this quarter, up just slightly from $3.01 million last quarter.
It’s far too early to call this a trend, but I’ll be eagerly awaiting year-end lobbying tallies, which are due out in January.
Drug makers have typically spared no expense lobbying the federal government and in recent years have steadily increased the money they spend on lobbying, but that doesn’t seem to be the case this quarter. Take Johnson & Johnson, for example, which spent $810,000 on lobbying this quarter. That’s way down from the $2.15 million they spent last quarter and the $1.9 million the company spent this time last year. The difference in spending isn’t quite so stark for most companies and groups, to be fair — BIO, for example, spent $3.08 million this quarter, up just slightly from $3.01 million last quarter.
It’s far too early to call this a trend, but I’ll be eagerly awaiting year-end lobbying tallies, which are due out in January.
.png)
No hay comentarios:
Publicar un comentario